
    
      Design: Observational, multicentre, longitudinal, prospective registry Primary objective: To
      evaluate the real life efficacy and safety of anti-TNF inhibitors in patients with RA using a
      prospective national registry.

      Target population: Patients initiating anti-TNF therapy for RA (including infliximab,
      adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according
      to their arrival on the market) Number of patients and centres : More than 80 centers in
      France (hospital-based, public and private practice) Recruitment period: 3 years Follow-up: 5
      years
    
  